Trials / Recruiting
RecruitingNCT05191680
TherApeutics in Early ProState Cancer (TAPS02)
Targeted Drug Intervention in Men at Risk of Progression on Active Surveillance for Early Prostate Cancer: A Randomised Trial - Therapeutics in Active Prostate Cancer Surveillance (TAPS02).
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2, randomised, multicentre, double-blind, placebo-controlled trial investigating the use of short term androgen deprivation therapy in the form of apalutamide (Erleada) in men on active surveillance for prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apalutamide Oral Tablet [Erleada] | Apalutamide is a selective Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR. |
| DRUG | Placebo | Placebo to match apalutamide |
Timeline
- Start date
- 2023-04-24
- Primary completion
- 2029-10-01
- Completion
- 2029-10-01
- First posted
- 2022-01-13
- Last updated
- 2025-06-20
Locations
6 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05191680. Inclusion in this directory is not an endorsement.